Biotechnology - Prosensa


Current filters:


Popular Filters

Promising mid-stage results for Prosensa’s drisapersen in DMD boys


Shares of Dutch biotech firm Prosensa Holding rose 3.85% to $7.02 after the firm reported encouraging…

BiotechnologydrisapersenGlaxoSmithKlineProsensaRare diseasesResearch

GlaxoSmithKline returns Duchenne drug rights to Prosensa

GlaxoSmithKline returns Duchenne drug rights to Prosensa


UK pharma giant GlaxoSmithKline says that its partner, Dutch biotech firm Prosensa has regained all rights…

BiotechnologydrisapersenGlaxoSmithKlineLicensingProsensaRare diseases

Prosensa raises 23 million euros


Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases…

BiotechnologyFinancialProsensaRare diseasesResearch

Prosensa to get milestone payments from GSK under Duchenne collaboration


Dutch biotech company Prosensa, focusing on rare diseases with an unmet medical need, has agreed with…

BiotechnologyFinancialGlaxoSmithKlineLicensingPharmaceuticalProsensaRare diseasesResearch

Back to top